Alzheimer’s disease progression by geographical region in a clinical trial setting

Table 1 Number of sites, enrolled subjects and subjects completing the study by country and region

Region/country	Number of sites	Number enrolled	Completers, n (%) ^a
Region/country	Number of sites	Number enrolled	EXPEDITION	IDENTITY ^b
North America	179	832	325 (72)	140 (37)
United States	154	714	286 (71)	127 (41)
Canada	25	118	39 (80)	13 (19)
Western Europe/Israel	112	412	163 (77)	71 (36)
Belgium	4	8	–	5 (63)
Denmark	2	5	–	3 (60)
Finland	3	6	–	6 (100)
France	16	69	23 (92)	9 (20)
Germany	23	104	42 (76)	14 (29)
Israel	7	22	–	8 (36)
Italy	18	74	42 (74)	1 (6)
Spain	16	48	15 (63)	12 (50)
Sweden	12	37	23 (85)	8 (80)
United Kingdom	11	39	18 (72)	5 (36)
South America /Mexico	50	196	82 (75)	8 (9)
Argentina	25	88	43 (67)	0
Brazil	14	67	39 (85)	0
Chile	7	17	–	8 (47)
Mexico	4	24	–	0
Eastern Europe/Russia	49	195	38 (61)	5 (4)
Bulgaria	5	18	–	1 (6)
Hungary	4	16	–	1 (6)
Poland	13	48	24 (67)	3 (25)
Romania	4	17	–	0
Russia	11	45	14 (54)	0
Serbia	3	8	–	0
Turkey	4	23	–	0
Ukraine	5	20	–	0
Japan	46	191	71 (88)	23 (21)
Asia	40	169	59 (84)	0
China	6	22	–	0
India	7	10	–	0
Korea	16	85	33 (79)	0
Taiwan	11	52	26 (93)	0
Australia/South Africa	25	84	32 (84)	18 (39)
Australia	18	58	32 (84)	10 (50)
South Africa	7	26	–	8 (31)

^aFor the EXPEDITION program, a completer was defined as a subject who had completed the 80-week double-blind study period. For the IDENTITY program, a completer was defined as a subject who had completed the 76-week initial treatment period; the denominator in this case was the number of subjects who had opportunity to complete 76 weeks of treatment before the study drug was stopped at request of the sponsor, and the study was amended.
^bSeveral countries were included only in the IDENTITY program (Belgium, Denmark, Finland, Israel, Chile, Mexico, Bulgaria, Hungary, Romania, Serbia, Turkey, Ukraine, China, India and South Africa).

ISSN: 1758-9193